U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07638982) titled 'Axatilimab + CAR-T for High-Risk Lymphoma' on June 05.
Brief Summary: Axatilimab + CAR-T in High-Risk Lymphoma
Study Start Date: Oct. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B Cell Lymphoma (DLBCL)
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma (HGBCL)
High-Grade B-Cell Lymphoma, Nos
PMBCL
Follicular Grade 3 Lymphoma
Intervention:
DRUG: Axatilimab
Dose Level -1: 0.1mg/kg Dose Level +1: 0.3mg/kg Dose Level +2: 1mg/kg Dose Level +3: 3mg/kg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Northside Hospital, Inc.
Disclaimer: Curated by HT Syndic...